Clinical trials
Antibody clinical trials
Below are recruiting antibody clinical trials, each written for real people, not researchers. We’re tracking 539 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06152575RecruitingPhase 3
Study of elranatamab for multiple myeloma that returned after other treatments
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
Mobile, AlabamaAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+ - NCT07142239Recruiting
Blood markers in primary vs. secondary antiphospholipid syndrome
This study looks at three blood markers (MPV, PLR, and NLR) in people with antiphospholipid syndrome (APS) to see if they differ between primary APS (no other autoimmune disease) and secondary APS (with lupus or another autoimmune condition). It may help doctors better understand and manage APS.
Al Khārjah, Kharga OasisAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT07479485RecruitingPhase 1/Phase 2
MRG006A combo for advanced liver cancer
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06417892Recruiting
Fruquintinib combo with or without immunotherapy for stomach cancer
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Canoga Park, CaliforniaAges 18–75 - NCT07724223RecruitingPhase 2
Combination targeted therapy for advanced colorectal cancer
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07724496Recruiting
H. pylori and stomach growth features study
This study looks at whether having H. pylori infection (a common stomach bacteria) and certain features of stomach growth can predict how early stomach cancer or pre-cancerous changes will behave and what your long-term outlook might be. You may be eligible if you are being treated with a camera-based removal procedure called endoscopic submucosal dissection (ESD).
Beijing, Beijing MunicipalityAges 18–80 - NCT06072482RecruitingPhase 4
Avacopan for ANCA vasculitis (GPA or MPA)
This study tests an oral medication called avacopan for people with active ANCA-associated vasculitis (GPA or MPA). It’s for those who need strong treatment to control their disease and aims to see if avacopan works as well as standard therapies.
Anchorage, AlaskaAges 18–100 - NCT07698197Recruiting
Exercise study for immune system problems
This study tests if a moderate exercise program can help people with certain antibody deficiencies. It aims to see if exercise improves immune function in people who are not taking immunoglobulin therapy.
Milford, ConnecticutAges 18–65 - NCT06528496RecruitingPhase 2
Less chemo plus antibody therapy for high-risk neuroblastoma in children
This study tests whether giving fewer chemotherapy drugs along with other targeted therapies (monoclonal antibodies) works well for children with high-risk neuroblastoma. It aims to reduce side effects while still treating the cancer effectively.
New York, New YorkAges 1.5 years–19 years - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Duarte, CaliforniaAges 18 years+ - NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
La Jolla, CaliforniaAges 18 years+ - NCT07713485RecruitingPhase 1
XmAb412 study in healthy adults
This is a first-in-human study testing a new drug called XmAb412 in healthy volunteers. It helps researchers understand how the drug works in the body and if it's safe.
Joondalup, Western AustraliaAges 18–55 - NCT07714512RecruitingPhase 1/Phase 2
Anti-CD38 antibody for severe aplastic anemia not helped by other treatments
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07186842RecruitingPhase 1/Phase 2
Testing the safety of BNT329 for advanced CA19-9 positive tumors
This trial tests if the investigational drug BNT329 is safe and could help people with advanced solid tumors that make a marker called CA19-9. It is for those who have tried standard treatments and need new options.
Denver, ColoradoAges 18 years+ - NCT06688331RecruitingPhase 2
Treating early stage 1 type 1 diabetes in children with cell therapy and antibody
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
BialystokAges 3–18 - NCT07039422RecruitingPhase 2
Ianalumab re-treatment for ITP or wAIHA
This trial tests a re-treatment with ianalumab for people with ITP or warm-antibody autoimmune hemolytic anemia who previously benefited from the drug in an earlier Novartis study but then had their condition return after at least 2 years. It aims to see if a second course can help again.
Buenos AiresAges 18–100 - NCT07665190RecruitingPhase 2
New drug combination before surgery for advanced throat cancer
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT03290456Recruiting
Prednisone plus rituximab to help keep ANCA vasculitis in remission
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
AmiensAges 18 years+ - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03729752RecruitingPhase 1
PET scan to study an HIV-fighting antibody in the body
This Phase 1/early study uses a special PET scan to see where an HIV-targeting antibody (VRC01) goes in the body. The study may help researchers understand how well this antibody reaches HIV-related targets, which could guide future HIV treatments or vaccines.
San Francisco, CaliforniaAges 18 years+
Hear when a new Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody?
- Yes. Clin2 currently lists 539 recruiting antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.